NCT00160745 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Ott C, Raff U, Schneider MP, Titze SI, Schmieder RE
25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clin Res Cardiol. 2013 Apr;102(4):299-304. doi: 10.1007/s00392
Ott C, Ritt M, Titze SI, Schäufele T, Schmieder RE
Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. J Nephrol. 2009 Sep-Oct;22(5):675-81.
Ott C, Schlaich MP, Schmidt BM, Titze SI, Schäufele T, Schmieder RE
Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008 Feb;196(2):704-11. Epub 2007 Feb 12.
Ott C, Schneider MP, Schlaich MP, Schmieder RE
Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvasc Res. 2012 Jul;84(1):60-4. doi: 10.1016/j.mvr.2012.03.007. Epub 2012 Mar 29.

A Randomised, Double-blind, Placebo-controlled, Mono-centre, Explorative Phase II Trial to Study the Effects of Rosuvastatin on Basal Production and Release of Nitric Oxide From the Renal Vasculature in Patients With Hypercholesterolemia.

Details for clinical trial NCT00160745

Clinical trial NCT00160745 - References